These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21861992)

  • 1. Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravis.
    Allman W; Saini SS; Tuzun E; Christadoss P
    Cell Immunol; 2011; 271(2):292-8. PubMed ID: 21861992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
    Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis.
    Milani M; Ostlie N; Wu H; Wang W; Conti-Fine BM
    J Neuroimmunol; 2006 Oct; 179(1-2):152-62. PubMed ID: 16945426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
    J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
    Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
    Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of B-cells in experimental myasthenia gravis in mice.
    Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
    Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Morgan BP; Christadoss P
    J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
    Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
    J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of prophylactic effects of nasal tolerance with a dual analogue on experimental autoimmune myasthenia gravis in young mice].
    Liu SL; Huang Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):191-4. PubMed ID: 18433545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
    Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
    J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
    Zoda T; Yeh TM; Krolick KA
    J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.
    Schaffert H; Pelz A; Saxena A; Losen M; Meisel A; Thiel A; Kohler S
    Eur J Immunol; 2015 May; 45(5):1339-47. PubMed ID: 25676041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis.
    Nessi V; Nava S; Ruocco C; Toscani C; Mantegazza R; Antozzi C; Baggi F
    J Immunol; 2010 Nov; 185(9):5656-67. PubMed ID: 20881192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
    J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.